The rapid genome testing shortened the average precise genetic diagnosis time from nearly ten months to under two weeks. Credit: Mongkolchon Akesin / Shutterstock. · Medical Device Network · ...
Hosted on MSN
GeneDx outlines $540M–$555M 2026 revenue target as company accelerates market expansion with new sales force
Katherine Stueland, President and CEO, indicated that "the fourth quarter was a strong finish to a transformative year for GeneDx," reporting quarterly revenues of $121 million and full year revenues ...
Genomic screening identified conditions missed by standard approaches due to atypical presentations or the absence of biochemical biomarkers, including hearing loss in infants who passed their initial ...
GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will ...
GeneDx Holdings offers AI-driven health intelligence solutions, leveraging the Centrellis platform to analyze clinical and genomic data for disease understanding and personalized healthcare. It ...
GeneDx Holdings Corp. (WGS) specializes in delivering precise medical diagnostic insights through its expertise in genomic sequencing, data science, and a vast rare disease dataset. The company has ...
GeneDx Holdings Corp. delivers AI-driven health intelligence solutions, leveraging its platform to analyze multidimensional clinical and genomic data for patient care and disease management. The ...
Hosted on MSN
GeneDx raises 2025 revenue guidance to $428M amid accelerating exome and genome test growth
GeneDx raised full year 2025 total revenue guidance to $425 million to $428 million. Exome and genome revenue guidance was increased to $358 million to $361 million, reflecting 53% to 55% growth for ...
What's interesting about GeneDx's tumble is that its first-quarter performance was, on the surface, rather good. The figures released Wednesday revealed the DNA testing company managed to boost its ...
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the third ...
GeneDx leverages a vast rare disease database and advanced genomic testing, offering superior insights over traditional panel testing. The company achieved a significant turnaround, becoming cash flow ...
GeneDx (NASDAQ:WSG) announced plans on Wednesday to acquire Fabric Genomics, a pioneer in AI-powered genomic interpretation, to create a leading platform for rare disease diagnostics and newborn ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results